What pharmaceutical competitive intelligence solutions should do

A pharmaceutical CI solution should convert fragmented external evidence into an organized view of a target, mechanism, asset, indication, company, or market event. At minimum, it should help users find the underlying record, understand when it changed, connect related entities, and explain how an analyst reached a conclusion.

Patsnap Eureka Life Sciences supports competitive-intelligence workflows that combine patent, literature, clinical, and other biopharma evidence; its current Life Sciences page also presents Pulse monitoring and Pharma CI Explorer within the product line.¹ It is a research and intelligence platform, not a substitute for scientific, clinical, regulatory, legal, or investment review.

Build the evidence layer before the dashboard

Clinical development

Clinical registries reveal study design, status, sponsors, interventions, outcomes, and amendments, subject to each record’s reporting quality and update behavior. The ClinicalTrials.gov API provides a documented route to study records and publishes a data timestamp so users can check the latest refresh.² A CI workflow should preserve the source record and the date on which a change was observed.

Regulatory and product status

Regulatory evidence should come from the relevant authority. In the United States, the FDA Orange Book identifies approved drug products under the applicable framework and includes related patent and exclusivity information.³ Drugs@FDA provides approval information and product labeling for covered products.⁴ Teams should avoid collapsing approval, launch, availability, reimbursement, and commercial success into one field.

Scientific and technical evidence

Publications, conference materials, preprints, patents, and company disclosures answer different questions and carry different review standards. Record document type, publication date, sponsor or author, study context, and whether the finding is peer reviewed, preliminary, retrospective, or company reported.

Patent and exclusivity signals

Patent families, claims, legal events, assignees, inventors, citations, and filing geography can reveal technical direction and portfolio activity. However, a patent publication is not proof that a program works, that a product will launch, or that a company has freedom to operate.

Match the solution to the CI workflow

One platform may cover several workflows, but buyers should test each separately. Search quality, entity resolution, monitoring, document analysis, structured exports, and executive reporting are different capabilities. A good landscape tool may not provide reliable alerts, and a fast alert feed may not support deep scientific review.

For patent-specific questions inside a wider pharmaceutical CI program, Patsnap Eureka IP Search offers novelty and FTO search workflows that build strategies from technical or product descriptions and organize source-linked evidence for expert review.⁵ This is a separate IP workflow; claim interpretation and legal conclusions still require qualified professionals.

How to evaluate pharmaceutical competitive intelligence solutions

1. Coverage that matches the decision

List the jurisdictions, registries, regulators, patent offices, publication types, conferences, companies, and deal sources that matter. Then test known records and known edge cases. Broad coverage claims are less useful than proof that the system retrieves the evidence your team routinely needs.

2. Entity resolution and lineage

Check how the solution handles drug codes, generic and brand names, targets, modalities, indications, trial identifiers, companies, subsidiaries, licensees, patent families, and ownership changes. Every normalized field should remain traceable to the original record.

3. Change detection and alert controls

Test whether alerts identify what changed, when it changed, the prior value, the current value, and the source. Review deduplication, materiality rules, watchlist governance, delivery channels, and the process for correcting false matches.

4. Analytical transparency

Analysts should be able to separate quoted evidence, extracted facts, calculated fields, model-generated summaries, and human interpretation. Ask how citations resolve, how search logic is saved, and how a reviewer can reproduce an answer.

5. Workflow, exports, and governance

Evaluate project spaces, comments, permissions, audit history, exports, APIs, retention settings, and integration with the team’s existing tools. Confirm plan-specific availability, security documentation, data handling, and support directly with the vendor.

Build a pharmaceutical CI operating model

1. Assign decisions and owners. Tie each topic to a committee, asset team, portfolio lead, business-development owner, or IP lead.
2. Create a source policy. Define authoritative sources, acceptable secondary sources, evidence labels, and citation requirements.
3. Set a taxonomy. Standardize entities, event types, status values, indications, modalities, and confidence labels.
4. Design escalation rules. Decide which changes require immediate review and which belong in periodic briefs.
5. Separate facts from implications. Preserve the record, then add analyst interpretation, counterarguments, and decision impact.
6. Measure usefulness. Review missed events, false alerts, time to verify, stakeholder adoption, and decisions changed—not the volume of content collected.

Pharmaceutical competitive intelligence solutions: FAQ